CN114656465A - 一种阿维巴坦钠的制备方法 - Google Patents
一种阿维巴坦钠的制备方法 Download PDFInfo
- Publication number
- CN114656465A CN114656465A CN202011537247.9A CN202011537247A CN114656465A CN 114656465 A CN114656465 A CN 114656465A CN 202011537247 A CN202011537247 A CN 202011537247A CN 114656465 A CN114656465 A CN 114656465A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- reaction
- ammonium
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- RTCIKUMODPANKX-JBUOLDKXSA-M avibactam sodium Chemical compound [Na+].NC(=O)[C@@H]1CC[C@H]2N(OS([O-])(=O)=O)C(=O)N1C2 RTCIKUMODPANKX-JBUOLDKXSA-M 0.000 title claims abstract description 16
- 229960001496 avibactam sodium Drugs 0.000 title claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims abstract description 20
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims abstract description 16
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000001099 ammonium carbonate Substances 0.000 claims abstract description 14
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003054 catalyst Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical group [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims abstract description 12
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000852 hydrogen donor Substances 0.000 claims abstract description 12
- 238000005915 ammonolysis reaction Methods 0.000 claims abstract description 10
- 235000012501 ammonium carbonate Nutrition 0.000 claims abstract description 8
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims abstract description 6
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims abstract description 6
- 235000019270 ammonium chloride Nutrition 0.000 claims abstract description 6
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims abstract description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims abstract description 5
- 235000011130 ammonium sulphate Nutrition 0.000 claims abstract description 5
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 5
- 238000007098 aminolysis reaction Methods 0.000 claims abstract description 4
- -1 piperidine-2-carboxylic acid ethyl ester oxalate Chemical compound 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 230000006315 carbonylation Effects 0.000 claims description 6
- 238000005810 carbonylation reaction Methods 0.000 claims description 6
- 238000006264 debenzylation reaction Methods 0.000 claims description 6
- PYUXATUBICTSNB-DFQHDRSWSA-N ethyl (2s,5r)-5-(phenylmethoxyamino)piperidine-2-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.C1N[C@H](C(=O)OCC)CC[C@H]1NOCC1=CC=CC=C1 PYUXATUBICTSNB-DFQHDRSWSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000006277 sulfonation reaction Methods 0.000 claims description 5
- MCZDHTKJGDCTAE-UHFFFAOYSA-M tetrabutylazanium;acetate Chemical compound CC([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC MCZDHTKJGDCTAE-UHFFFAOYSA-M 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 2
- NTZRDKVFLPLTPU-UHFFFAOYSA-N CC[Na] Chemical compound CC[Na] NTZRDKVFLPLTPU-UHFFFAOYSA-N 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 8
- 229910052708 sodium Inorganic materials 0.000 abstract description 8
- 239000011734 sodium Substances 0.000 abstract description 8
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 abstract description 4
- 239000005660 Abamectin Substances 0.000 abstract description 4
- 229950008167 abamectin Drugs 0.000 abstract description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 abstract description 4
- 239000007868 Raney catalyst Substances 0.000 abstract description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 abstract description 3
- 229910000564 Raney nickel Inorganic materials 0.000 abstract description 3
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000000126 substance Substances 0.000 description 13
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000001291 vacuum drying Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- LQVMZVKOVPITOO-UHFFFAOYSA-N 9h-fluoren-1-ylmethyl carbonochloridate Chemical compound C1C2=CC=CC=C2C2=C1C(COC(=O)Cl)=CC=C2 LQVMZVKOVPITOO-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000036209 Intraabdominal Infections Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical group O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-N sodium;sulfuric acid Chemical compound [H+].[H+].[Na+].[O-]S([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-N 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种阿维巴坦钠的制备方法,该方法以(2S,5R)‑5‑[(苄氧基)氨基]哌啶‑2‑羧酸乙酯草酸盐Ⅱ为起始原料先氨解生成化合物Ⅲ,然后成环得到化合物Ⅳ,化合物Ⅳ在催化剂作用下与供氢体反应得到化合物Ⅴ,再经磺化、成钠盐得到阿维巴坦钠。氨解试剂选自氯化铵、碳酸铵、硫酸铵、碳酸氢铵、甲酸铵;催化剂选自钯碳、二氧化铂或雷尼镍,所述供氢体选自环己烯、环己二烯或者四氢化萘。本方法收率高、安全性好、反应条件温和。
Description
技术领域
本发明属于医药技术领域,具体涉及一种阿维巴坦钠的制备方法。
背景技术
阿维巴坦钠,英文名:Avibactam Sodium,化学名称:[(1R,2S,5R)-2-(氨基羰基)-7-氧代-1,6-二氮杂双环[3.2.1]辛-6-基]硫酸一钠盐,化学结构式如下。
阿维巴坦钠与头孢菌素类抗菌药物头孢他啶组成固定配比剂量的复方制剂,并于2015年2月15日美国FDA批准上市,用于治疗成人复杂性腹腔内感染及复杂性***,适用于治疗肾脏感染(肾盂肾炎)患者。
目前文献报道的该阿维巴坦钠的制备方法主要有以下几种:专利文献(CN01816700)报道了如路线一所示的阿维巴坦钠的制备方法,该路线酰胺化步骤使用氨甲醇溶液反应时间长,产物需要柱纯化;氢化脱苄过程使用氢气作为供氢体,危险性较高,部分中间体不稳定后处理过程容易分解产生杂质,不适合工业化放大生产。
路线一:
专利文献(CN201280029765)报道了如路线二所示的阿维巴坦钠的制备方法,该路线氨解过程中使用氨甲醇溶液,氨易挥发,气味较大,需要进行特殊防护,并且导致反应时间长,需要多次补加氨甲醇溶液。氢化过程使用氢气作为供氢体还原危险性较高,反应操作过程繁琐,部分中间体不稳定后处理过程容易分解产生杂质,不适合工业化放大生产。
路线二:
专利文献(201610170439.8)公布了在钯碳催化下,使用三乙基硅烷脱除苄基的方法。
发明内容
本发明克服了上述现有技术的不足,提供了一种阿维巴坦钠的制备方法。该方法以(2S,5R)-5-[(苄氧基)氨基]哌啶-2-羧酸乙酯草酸盐为起始原料,并在氨解反应中氨解试剂选自氯化铵、碳酸铵、硫酸铵、碳酸氢铵、甲酸铵;脱苄反应中催化剂选自钯碳、二氧化铂或雷尼镍,所述供氢体选自环己烯、环己二烯或者四氢化萘。该方法原料廉价易得,反应条件温和,操作简单,安全性更高,收率高,纯度好,适合规模化工业大生产。
为了实现上述目标,本发明采用如下的技术方案:
一种阿维巴坦钠的制备方法,包括以下具体步骤:
(1)制备化合物Ⅲ(氨解反应):(2S,5R)-5- [(苄氧基)氨基]哌啶-2-羧酸乙酯草酸盐在有机溶剂和氨解试剂的存在下,反应得到化合物Ⅲ;
(2)制备化合物Ⅳ(成环反应):9-芴基甲氧基羰基保护化合物Ⅲ哌啶环上的氮,使用羰基化试剂来形成羰基化中间体,在碱存在下脱去Fmoc,然后环合得到化合物Ⅳ;
(3)制备化合物Ⅴ(脱苄反应):化合物Ⅳ在催化剂作用下与供氢体反应得到化合物Ⅴ的溶液:
(4)制备化合物Ⅰ(磺化反应):所得反应液分别加入缚酸剂、磺化试剂,搅拌反应至反应完毕,加入四丁基乙酸铵,搅拌反应至反应完毕,静置分层,二氯甲烷萃取、浓缩得到化合物Ⅰ;
(5)制备阿维巴坦钠:溶剂溶解化合物Ⅰ,加入2-乙基-己酸钠的乙醇溶液,过滤干燥得到阿维巴坦钠。合成路线如下:
其中,
步骤(1)中的溶剂选自甲醇、乙醇、异丙醇、二氧六环,优选甲醇;
步骤(1)氨解试剂选自氯化铵、碳酸铵、硫酸铵、碳酸氢铵、甲酸铵,优选碳酸铵;
步骤(2)所述羰基化试剂选自羰基二咪唑、碳酸二甲酯、氯甲酸酯、三
光气的至少一种,优选羰基二咪唑;
步骤(2)所述碱选自二乙胺、哌啶、吗啉、环己胺、对二甲基氨基吡啉、氢氧化钠、氢氧化钾、氢氧化锂的至少一种,优选二乙胺;
步骤(3)中的催化剂选自钯碳、二氧化铂或雷尼镍,优选钯碳;
步骤(3)中的供氢体选自环己烯、环己二烯或四氢化萘,优选环己烯;
步骤(4)磺化试剂选自氯磺酸,氨基磺酸或氨基磺酰氯,优选氨基磺酸;
步骤(4)缚酸剂选自碳酸钠,碳酸氢钠,氢氧化钠,碳酸钾,碳酸氢钾或氢氧化锂,优选碳酸钠;
步骤(5)溶剂选自乙醇/水混合物、异丙醇/水混合物和丙醇/水混合物中的任一种,优选乙醇/水混合物;
各步骤的投料配比如下:
步骤(1)中化合物Ⅱ与氨解试剂摩尔比为1:1~10;
步骤(2)中化合物Ⅲ与羰基化试剂摩尔比为1:2.5~3.5,化合物Ⅲ与碱的摩尔比为1:3.5~4.5;
步骤(3)中化合物Ⅳ与催化剂摩尔比为1:0.05~0.3,化合物Ⅳ与供氢体摩尔比为1:0.5~10;
步骤(4)化合物Ⅴ与磺化试剂的摩尔比为1:1~1.5,化合物Ⅴ与碱的摩尔比为1:0.1~0.5;
步骤(5)化合物Ⅰ与2-乙基-己酸钠的摩尔比为1:1~1.4。
各步骤反应条件如下:
步骤(1)反应温度可以在0~40℃进行,优选20~30℃;
步骤(2)反应温度可以在10~40℃进行,优选25~35℃;
步骤(3)反应温度可以在60~90℃进行,优选70~80℃;
步骤(4)反应温度可以在10~40℃进行,优选25~35℃;
步骤(5)反应温度可以在10~40℃进行,优选25~35℃。
本发明的有益之处在于:(1)本发明中氨解反应试剂选自氯化铵、碳酸铵、硫酸铵、碳酸氢铵、甲酸铵,避免了现有技术中使用氨/甲醇溶液导致的反应时间长,试剂易挥发等缺点;(2)脱苄反应中,选择催化转移氢化,避免了现有技术中的氢气的使用,改用环己烯、环己二烯或四氢化萘作为供氢体,操作简单,常压下就反应,增加安全系数,降低了生产成本,适合规模化大生产。
具体实施方式
以下结合具体实施例对本发明作具体的介绍。
实施例1
(1)制备化合物Ⅲ
3L三口瓶中加入起始物料(2S,5R)-5-[(苄氧基)氨基]哌啶-2-羧酸乙酯草酸盐200 g(0.543 mol),甲醇2L,碳酸铵156.6g(1.63 mol,3eq),20-30℃反应10h,过滤,滤液减压浓缩至干(真空度≤-0.08 Mpa),加入1L甲苯80℃打浆1h,过滤。湿品45℃真空干燥10h(真空度≤-0.09 Mpa)。得化合物Ⅲ 121.7 g ,收率90%,纯度99.6%。
(2)制备化合物Ⅳ
反应体系始终氮气保护。化合物Ⅲ 120 g(0.481 mol)中加入0.5 L氯苯,N,N-二异丙基乙胺69.5g(0.538 mol)后控温10-15℃滴加芴甲氧羰酰氯(138.9g,0.538mol)的氯苯(0.5L)溶液,升温至25-30℃反应3小时,控温10-15℃分三批加入羰基二咪唑(194.6g,1.2 mol,2.5eq),滴加二乙胺(123.1 g,1.207mol,3.5eq),升温至25-35℃反应6小时,35℃滴加1L醋酸,5-8℃保温析晶2小时,过滤,滤饼45℃真空干燥10h(真空度≤-0.09 Mpa),得化合物Ⅳ 118.3 g,收率89.4%,纯度98.6%。
(3)制备化合物Ⅴ
将化合物Ⅳ(27.5g,0.1mol)溶于甲醇(300ml),搅拌溶解,加入环己二烯(8g,0.1mol,1eq),投入反应瓶中,10%Pd/C催化剂(2.75g,0.1eq),升温至回流反应。反应结束,过滤催化剂,滤液减压浓缩至100ml,滴加至1000ml水中,析出大量固体,过滤得到白色固体。化学纯度98.8%,直接投下一步反应。
(4)制备化合物Ⅰ
上步所得IV(0.1mol计),异丙醇100ml,水100ml,氨基磺酸(11.7 g,0.12 mol,1.2eq),碳酸钠(27.6g,0.26 mol,0.26eq),20-30℃反应8-10小时,过滤,水相中加入四丁基乙酸铵(45g,0.15mol),搅拌1.5h,0.5L二氯甲烷萃取,45℃减压浓缩至干(真空度≤-0.05Mpa),100mL 丙酮0-5℃保温析晶2小时。过滤,湿品45℃真空干燥6-8h(真空度≤-0.09Mpa)。得化合物Ⅰ 32.9 g,两步收率65%,化学纯度99.2%。
(5)制备阿维巴坦钠
化合物Ⅰ(30.4g,0.06mol)溶于300 ml乙醇和15mL水中,加入活性炭搅拌0.5h,过滤,滤液中分批加入2-乙基己酸钠(9.97g,0.06mol,1eq),控温25-35℃搅拌2h,过滤。滤饼45℃真空干燥得阿维巴坦钠(真空度≤-0.09Mpa),收率65%,化学纯度99.9%。
实施例2
(1)制备化合物Ⅲ
1L三口瓶中加入起始物料(2S,5R)-5-[(苄氧基)氨基]哌啶-2-羧酸乙酯草酸盐50g(0.14 mol),甲醇0.5L,氯化铵7.5 g(0.14 mol,1eq),20-30℃反应10h,过滤,滤液减压浓缩至干(真空度≤-0.08 Mpa),加入1L甲苯80℃打浆1h,过滤。湿品45℃真空干燥10h(真空度≤-0.09 Mpa)。得化合物Ⅲ 32.4 g ,收率93%,纯度99.8%。
(2)制备化合物Ⅳ
反应体系始终氮气保护。化合物Ⅲ 32 g(0.13 mol)中加入0.2 L氯苯,N,N-二异丙基乙胺18.8g(0.14 mol)后控温10-15℃滴加芴甲氧羰酰氯(37.1 g,0.14mol)的0.5L氯苯溶液,升温至25-30℃反应3小时,控温10-15℃分三批加入羰基二咪唑(63.2g,0.39mol,3eq),滴加二乙胺(38.1g,0.52mol,4eq),升温至25-35℃反应6小时,35℃滴加1L醋酸,5-8℃保温析晶2小时,过滤,滤饼45℃真空干燥10h(真空度≤-0.09 Mpa),得化合物Ⅳ 33.2g,收率92.8%,纯度99.3%。
(3)制备化合物Ⅴ
将化合物Ⅳ(27.5g,0.1mol)溶于甲醇(300ml),搅拌溶解,加入环己烯(4.1g,0.05mol,0.5eq),投入反应瓶中,10%Pd/C催化剂(1.4g,0.05eq),升温至回流反应。反应结束,过滤催化剂,滤液减压浓缩至100ml,滴加至1000ml水中,析出大量固体,过滤得到白色固体。化学纯度99.1%,直接投下一步反应。
(4)制备化合物Ⅰ
上步所得IV(0.1mol计),异丙醇100ml,水100ml,氯磺酸(11.2 g,0.1 mol,1eq),碳酸氢钠(0.84 g,0.01 mol,0.1eq),20-30℃反应8-10小时,过滤,水相中加入四丁基乙酸铵(45g,0.15mol),搅拌1.5h,0.5L二氯甲烷萃取,45℃减压浓缩至干(真空度≤-0.05Mpa),100mL 丙酮0-5℃保温析晶2小时。过滤,湿品45℃真空干燥6-8h(真空度≤-0.09Mpa)。得化合物Ⅰ 36.5 g,两步收率72%,化学纯度99.0%。
(5)制备阿维巴坦钠
化合物Ⅰ(30.4g,0.06mol)溶于300 ml异丙醇和15mL水中,加入活性炭搅拌0.5h,过滤,滤液中分批加入2-乙基己酸钠(9.97g,0.06mol,1eq),控温25-35℃搅拌2h,过滤。滤饼45℃真空干燥得阿维巴坦钠(真空度≤-0.09Mpa),收率68%,化学纯度99.7%。
实施例3
(1)制备化合物Ⅲ
1L三口瓶中加入起始物料(2S,5R)-5-[(苄氧基)氨基]哌啶-2-羧酸乙酯草酸盐50g(0.14 mol),甲醇0.5L,碳酸氢铵110 g(1.4 mol,10eq),20-30℃反应2h,过滤,滤液减压浓缩至干(真空度≤-0.08 Mpa),加入1L甲苯80℃打浆1h,过滤。湿品45℃真空干燥10h(真空度≤-0.09 Mpa)。得化合物Ⅲ 32.5 g ,收率96%,纯度99.4%。
(2)制备化合物Ⅳ
反应体系始终氮气保护。化合物Ⅲ 32 g(0.13 mol)中加入0.2 L氯苯,N,N-二异丙基乙胺18.8g(0.14 mol)后控温10-15℃滴加芴甲氧羰酰氯(37.1 g,0.14mol)的0.5L氯苯溶液,升温至25-30℃反应3小时,控温10-15℃分三批加入羰基二咪唑(74.6g,0.46mol,3.5eq),滴加二乙胺(43.2 g,0.59mol,4.5eq),升温至25-35℃反应3小时,35℃滴加1L醋酸,5-8℃保温析晶2小时,过滤,滤饼45℃真空干燥10h(真空度≤-0.09 Mpa),得化合物Ⅳ33.6 g,收率94%,纯度99.3%。
(3)制备化合物Ⅴ
将化合物Ⅳ(27.5g,0.1mol)溶于甲醇(600ml),搅拌溶解,加入四氢化萘(132 g,1mol,10eq),投入反应瓶中,10%Pd/C催化剂(8.2g,0.3eq),升温至回流反应。反应结束,过滤催化剂,滤液减压浓缩至100ml,滴加至1000ml水中,析出大量固体,过滤得到白色固体。化学纯度99.0%,直接投下一步反应。
(4)制备化合物Ⅰ
上步所得IV(0.1mol计),异丙醇100ml,水100ml,氨基磺酰氯(17.3 g,0.15 mol,1.5eq),碳酸钾(6.9 g,0.05 mol,0.5eq),20-30℃反应6小时,过滤,水相中加入四丁基乙酸铵(45g,0.15mol),搅拌1.5h,0.5L二氯甲烷萃取,45℃减压浓缩至干(真空度≤-0.05Mpa),100mL 丙酮0-5℃保温析晶2小时。过滤,湿品45℃真空干燥6-8h(真空度≤-0.09Mpa)。得化合物Ⅰ 34.9 g,两步收率69%,化学纯度99.1%。
(5)制备阿维巴坦钠
化合物Ⅰ(30.4g,0.06mol)溶于300 ml丙醇和15mL水中,加入活性炭搅拌0.5h,过滤,滤液中分批加入2-乙基己酸钠(13.95g,0.084mol,1.4eq),控温25-35℃搅拌2h,过滤。滤饼45℃真空干燥得阿维巴坦钠(真空度≤-0.09Mpa),收率72%,化学纯度99.8%。
Claims (4)
1.一种阿维巴坦钠的合成方法,其特征在于,包括以下具体步骤:
(1)制备化合物Ⅲ(氨解反应):(2S,5R)-5- [(苄氧基)氨基]哌啶-2-羧酸乙酯草酸盐在有机溶剂和氨解试剂的存在下,反应得到化合物Ⅲ;
(2)制备化合物Ⅳ(成环反应):9-芴基甲氧基羰基保护化合物Ⅲ哌啶环上的氮,使用羰基化试剂来形成羰基化中间体,在碱存在下脱去Fmoc,然后环合得到化合物Ⅳ;
(3)制备化合物Ⅴ(脱苄反应):化合物Ⅳ在催化剂作用下与供氢体反应得到化合物Ⅴ的溶液;
(4)制备化合物Ⅰ(磺化反应):所得反应液分别加入缚酸剂、磺化试剂,搅拌反应至反应完毕,加入四丁基乙酸铵,搅拌反应至反应完毕,静置分层,二氯甲烷萃取、浓缩得到化合物Ⅰ;
(5)制备阿维巴坦钠:加溶剂溶解化合物Ⅰ,加入2-乙基-己酸钠的乙醇溶液,过滤干燥得到阿维巴坦钠,合成路线如下:
所述步骤(1)中氨解试剂选自氯化铵、碳酸铵、硫酸铵、碳酸氢铵、甲酸铵,优选碳酸铵;
所述步骤(3)中供氢体选自环己烯、环己二烯或四氢化萘,优选环己烯。
2.根据权利要求1的制备方法,其特征在于,所述步骤(1)化合物Ⅱ与氨解试剂摩尔比为1:1~10。
3.根据权利要求1的制备方法,其特征在于,所述步骤(3)中化合物Ⅳ与供氢体摩尔比为1:0.5~10。
4.根据权利要求1的制备方法,其特征在于,所述步骤(5)所述的溶剂选自乙醇/水混合物、异丙醇/水混合物或丙醇/水混合物,优选乙醇/水混合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011537247.9A CN114656465A (zh) | 2020-12-23 | 2020-12-23 | 一种阿维巴坦钠的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011537247.9A CN114656465A (zh) | 2020-12-23 | 2020-12-23 | 一种阿维巴坦钠的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114656465A true CN114656465A (zh) | 2022-06-24 |
Family
ID=82025345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011537247.9A Pending CN114656465A (zh) | 2020-12-23 | 2020-12-23 | 一种阿维巴坦钠的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114656465A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115073458A (zh) * | 2022-07-04 | 2022-09-20 | 山东致泰医药技术有限公司 | 一种阿维巴坦钠的制备方法 |
-
2020
- 2020-12-23 CN CN202011537247.9A patent/CN114656465A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115073458A (zh) * | 2022-07-04 | 2022-09-20 | 山东致泰医药技术有限公司 | 一种阿维巴坦钠的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1276617C (en) | Catalyst for vapor-phase intramolecular dehydration reaction of alkanolamines | |
CN109467535B (zh) | 一种芬苯达唑的制备方法 | |
CN108440330B (zh) | 一种盐酸多西环素的制备方法 | |
SK285043B6 (sk) | Spôsob prípravy L-fenylefrín hydrochloridu | |
CN114656465A (zh) | 一种阿维巴坦钠的制备方法 | |
CN104387299B (zh) | 4-氨基-n-[(2r, 3s)-3-氨基-2-羟基-4-苯丁基]-n-异丁基苯磺酰胺的制备方法 | |
CN103508908B (zh) | 4-氨基-3-甲基苯酚的制备方法 | |
CN115108918B (zh) | 一种3,3`,4,4`-四氨基联苯的制备方法 | |
CN108033903B (zh) | 一种dl-对甲砜基苯丝氨酸乙酯带水酯化的合成工艺 | |
CN115368318B (zh) | 一种伏硫西汀的合成方法及应用 | |
CN111072498A (zh) | 一种化工中间体n-异丙基对氟苯胺的制备方法 | |
US3795707A (en) | Manufacture of alpha-6-deoxytetracyclines | |
CN108299259B (zh) | 2-氨基-5-苯硫基-(2-甲氧基)乙酰苯胺的制备方法 | |
CN115260085A (zh) | 一种高产率3-硝基-9-乙基咔唑的制备方法 | |
CN111423342A (zh) | 一种联产n-甲基-2-氟苯胺和结晶磺胺的制备方法 | |
CN111574416B (zh) | 一种以异硫脲盐与对甲基苯磺酸截短侧耳素酯制备泰妙菌素的方法 | |
CN111574458B (zh) | 一种麦角硫因的合成方法 | |
CN114436864A (zh) | 一种2-甲基-5氨基苯酚的制备方法 | |
CN111196760A (zh) | 一种盐酸托莫西汀的制备方法 | |
CN112851508A (zh) | 一种巴洛沙韦中间体的制备方法 | |
KR100286570B1 (ko) | 세리놀의 제조방법 | |
CN113402428B (zh) | 一种反式4-(叔丁氧羰氨基)环己烷羧酸及其中间体的制备方法 | |
CN108554456B (zh) | 一种稀土咪唑盐化合物作为催化剂的应用 | |
CN114213283B (zh) | 一锅法制备[2-[1-(Fmoc-氨基)乙氧基]乙氧基]乙酸的方法 | |
CN114105848B (zh) | 一种顺式-d-羟脯氨酸衍生物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |